Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Post by barmac6on Mar 14, 2011 8:15pm
226 Views
Post# 18284451

House Positions for HEM from 20110314 to 20110314

House Positions for HEM from 20110314 to 20110314

House Positions for HEM from 20110314 to 20110314

Ex House Bought $Value Ave Sold $Value Ave Net $Net
33 Canaccord 385,900 459,464 1.19 46,600 55,885 1.20 339,300 -403,579
9 BMO Nesbitt 8,200 9,652 1.18 1,400 1,638 1.17 6,800 -8,014
73 Cormark 3,200 3,776 1.18 0 3,200 -3,776
19 Desjardins 500 560 1.12 0 500 -560
89 Raymond James 590 702 1.19 300 360 1.20 290 -342
85 Scotia 11,500 13,612 1.18 12,000 14,096 1.17 -500 484
39 Merrill Lynch 0 800 960 1.20 -800 960
81 HSBC 0 1,000 1,180 1.18 -1,000 1,180
58 Qtrade 800 896 1.12 2,300 2,668 1.16 -1,500 1,772
99 Jitney 100 117 1.17 4,100 4,622 1.13 -4,000 4,505
124 Questrade 0 5,100 5,842 1.15 -5,100 5,842
80 National Bank 0 6,000 7,122 1.19 -6,000 7,122
2 RBC 7,800 9,078 1.16 14,700 17,301 1.18 -6,900 8,223
79 CIBC 8,300 9,892 1.19 17,380 20,597 1.19 -9,080 10,705
101 Newedge 5,800 6,871 1.18 15,600 18,318 1.17 -9,800 11,447
90 Barclays 0 11,700 13,819 1.18 -11,700 13,819
26 Commission Direct 0 37,300 45,256 1.21 -37,300 45,256
7 TD Sec 9,000 10,650 1.18 46,310 55,477 1.20 -37,310 44,827
1 Anonymous 500 600 1.20 219,600 260,729 1.19 -219,100 260,129
Total 442,190 525,870 1.19 442,190 525,870 1.19 0 0
Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse